Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.74 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5397091 | 0.85 | PTGDR2 (1.00) | PTGDR2LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL5404990 | 0.85 | PTGDR2 (1.00) | PTGDR2LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL5504734 | 0.85 | PTGDR2 (0.58) | PTGDR2LMNANPSR1MEN1KMT2A | |
| SCHEMBL27641688 | 0.84 | MAPT (0.55) | PTGDR2LMNASMN1; SMN2GFERNPSR1 | |
| SCHEMBL5513344 | 0.84 | PTGDR2 (0.56) | PTGDR2LMNANPSR1MEN1KMT2A | |
| SCHEMBL5444441 | 0.83 | PTGDR2 (0.52) | PTGDR2LMNASMN1; SMN2GFERNPSR1 | |
| SCHEMBL6281793 | 0.82 | PTGDR2 (0.51) | PTGDR2LMNASMN1; SMN2GFERNPSR1 | |
| SCHEMBL5440260 | 0.82 | PTGDR2 (0.65) | PTGDR2LMNASMN1; SMN2 | |
| SCHEMBL6276664 | 0.81 | PTGDR2 (0.53) | PTGDR2LMNASMN1; SMN2GFERNPSR1 | |
| SCHEMBL4130883 | 0.80 | PTGDR2 (0.71) | PTGDR2LMNASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556047-A2 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-07-27 | — | — | EP | claimed |
| WO-2004032848-A2 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-04-22 | — | — | WO | claimed |
| EP-1740547-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005100321-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| EP-1556356-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CRTH2 ANTAGONISTS | Warner-Lambert Company LLC (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004035543-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CRTH2 ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-04-29 | — | — | WO | disclosed |